VistaGen Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 40
- Market Cap
- $95.5M
- Website
- http://www.vistagen.com
- Introduction
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression diso...
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT06615557
- Locations
- 🇺🇸
Vistagen Clinical Site, Houston, Texas, United States
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT06358651
- Locations
- 🇺🇸
Vistagen Clinical Site, Everett, Washington, United States
AV-101 Alone and in Combination With Probenecid in Healthy Subjects
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05280054
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Glendale, California, United States
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 483
- Registration Number
- NCT05030350
- Locations
- 🇺🇸
VistaGen Investigational Site, Bellevue, Washington, United States
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 324
- Registration Number
- NCT05011396
- Locations
- 🇺🇸
VistaGen Clinical Center, Allentown, Pennsylvania, United States
🇺🇸VistaGen Clinical Site, Austin, Texas, United States
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 209
- Registration Number
- NCT04754802
- Locations
- 🇺🇸
VistaGen Clinical Sites, Fort Myers, Florida, United States
🇺🇸VistaGen Clinical Site, Bellevue, Washington, United States
PH94B in the Treatment of Adjustment Disorder With Anxiety
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04404192
- Locations
- 🇺🇸
VistaGen Clinical Site, New York, New York, United States
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04147949
AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT03078322
- Locations
- 🇺🇸
VistaGen Investigational Site, Bellevue, Washington, United States
Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- VistaGen Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT01483846
- Locations
- 🇺🇸
UCSD Medical Center, San Diego, California, United States